Arun J Sanyal Selected Research

nas

1/2022	Meta-analysis: analysis of mechanistic pathways in the treatment of non-alcoholic steatohepatitis. Evidence from a Bayesian network meta-analysis.
1/2022	Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms.
11/2020	A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study.
1/2020	Increased hepatic and circulating chemokine and osteopontin expression occurs early in human NAFLD development.
12/2019	The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials.
11/2019	Haptoglobin 2 Allele is Associated With Histologic Response to Vitamin E in Subjects With Nonalcoholic Steatohepatitis.
10/2019	Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.
1/2019	Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
1/2019	Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis.
1/2013	Multi-SNP analysis of GWAS data identifies pathways associated with nonalcoholic fatty liver disease.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Arun J Sanyal Research Topics

Disease

135	Fibrosis (Cirrhosis) 12/2022 - 01/2003
133	Non-alcoholic Fatty Liver Disease 12/2022 - 06/2003
44	Inflammation (Inflammations) 01/2022 - 06/2005
34	Liver Diseases (Liver Disease) 11/2022 - 05/2004
26	Alcoholic Fatty Liver 01/2022 - 01/2009
26	Insulin Resistance 10/2021 - 10/2002
25	Fatty Liver 11/2022 - 05/2003
19	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 10/2004
16	Liver Cirrhosis (Hepatic Cirrhosis) 11/2022 - 09/2013
14	End Stage Liver Disease 12/2021 - 10/2004
13	Infections 12/2019 - 05/2003
12	Obesity 01/2022 - 10/2006
12	Ascites 12/2021 - 03/2003
10	Hepatic Encephalopathy 01/2018 - 09/2005
9	Hemorrhage 01/2018 - 12/2003
8	Disease Progression 12/2022 - 01/2015
8	Portal Hypertension 01/2022 - 11/2005
8	Type 2 Diabetes Mellitus (MODY) 01/2022 - 09/2013
8	Alcoholic Hepatitis 11/2021 - 12/2005
8	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2020 - 01/2005
8	Chronic Hepatitis C 10/2014 - 05/2003
7	Hepatorenal Syndrome 01/2021 - 05/2008
6	Liver Neoplasms (Liver Cancer) 11/2022 - 08/2010
6	Neoplasms (Cancer) 01/2022 - 02/2008
6	Weight Loss (Weight Reduction) 12/2021 - 09/2013
6	Dyslipidemias (Dyslipidemia) 01/2020 - 08/2010
6	Hepatitis C 03/2018 - 07/2004
6	Acute Kidney Injury (Acute Renal Failure) 01/2018 - 08/2009
5	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 12/2013
4	Hepatitis B 10/2022 - 04/2007
4	Hypertension (High Blood Pressure) 01/2022 - 01/2019
4	Pruritus (Itching) 01/2022 - 03/2015
4	Nausea 10/2021 - 09/2008
4	Dysbiosis 01/2020 - 10/2016
4	Peritonitis 01/2010 - 12/2005
3	Hepatitis 01/2022 - 01/2013
3	Weight Gain 01/2022 - 08/2017
3	Anemia 10/2021 - 06/2005

Drug/Important Bio-Agent (IBA)

37	Biomarkers (Surrogate Marker)IBA 12/2022 - 05/2006
25	LipidsIBA 10/2022 - 10/2002
19	Pharmaceutical PreparationsIBA 11/2022 - 05/2003
19	Alanine Transaminase (SGPT)IBA 01/2022 - 01/2003
15	nasIBA 01/2022 - 06/2005
14	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022 - 10/2009
14	Glucose (Dextrose)FDA LinkGeneric 12/2021 - 10/2002
13	EnzymesIBA 01/2022 - 09/2008
12	Bile Acids and Salts (Bile Acids)IBA 12/2022 - 09/2013
12	obeticholic acidIBA 01/2022 - 09/2013
11	Vitamin E FDA LinkGeneric 11/2019 - 12/2004
10	MicroRNAs (MicroRNA)IBA 01/2022 - 12/2008
10	Pioglitazone (Actos)FDA Link 01/2020 - 12/2004
9	CollagenIBA 11/2022 - 10/2006
9	Proteins (Proteins, Gene)FDA Link 01/2022 - 10/2006
9	Insulin (Novolin)FDA Link 01/2021 - 10/2002
8	Lipoproteins (Lipoprotein)IBA 10/2022 - 12/2013
8	Antiviral Agents (Antivirals)IBA 03/2018 - 06/2005
8	Ribavirin (Virazole)FDA LinkGeneric 10/2014 - 05/2004
8	InterferonsIBA 07/2014 - 05/2004
7	CholesterolIBA 01/2022 - 05/2012
7	Fatty Acids (Saturated Fatty Acids)IBA 01/2022 - 06/2008
7	CytokinesIBA 01/2020 - 01/2005
7	Triglycerides (Triacylglycerol)IBA 01/2020 - 05/2012
6	Rifaximin (L 105)FDA Link 06/2022 - 02/2011
6	TerlipressinIBA 01/2021 - 12/2003
6	SodiumIBA 01/2021 - 03/2003
6	AlbuminsIBA 01/2021 - 12/2005
5	Hormones (Hormone)IBA 01/2022 - 05/2003
5	BilirubinIBA 12/2021 - 05/2006
5	CreatinineIBA 01/2021 - 08/2011
5	LDL CholesterolIBA 11/2020 - 05/2012
5	RNA (Ribonucleic Acid)IBA 01/2020 - 01/2003
5	LigandsIBA 01/2019 - 01/2013
4	oxidized low density lipoproteinIBA 01/2022 - 12/2013
4	DiamondIBA 01/2022 - 01/2016
4	AnticoagulantsIBA 10/2021 - 10/2006
4	LDL Lipoproteins (beta Lipoproteins)IBA 10/2021 - 05/2015
4	Transaminases (Aminotransferases)IBA 11/2020 - 09/2010
4	Fatty Acid Synthases (Fatty Acid Synthase)IBA 02/2020 - 01/2015
4	CaspasesIBA 01/2020 - 02/2012
4	DiureticsIBA 07/2009 - 03/2003
3	AcidsIBA 12/2022 - 01/2010
3	Sucrose (Saccharose)IBA 11/2022 - 01/2020
3	SugarsIBA 01/2022 - 12/2017
3	aldaferminIBA 01/2022 - 01/2021
3	aramcholIBA 01/2022 - 11/2017
3	simtuzumabIBA 01/2022 - 10/2018
3	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 12/2021 - 12/2017
3	HDL LipoproteinsIBA 11/2021 - 11/2013
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 10/2021 - 05/2012
3	Alkaline PhosphataseIBA 06/2021 - 09/2010
3	Protons (Proton)IBA 06/2021 - 10/2020
3	Biological ProductsIBA 05/2021 - 01/2013

Therapy/Procedure

55	Therapeutics 12/2022 - 03/2003
34	Liver Transplantation 11/2022 - 06/2003
9	Drug Therapy (Chemotherapy) 12/2021 - 11/2008
6	Transplantation 11/2019 - 10/2004
6	Surgical Portasystemic Shunt (Portosystemic Shunt) 04/2016 - 03/2003
6	Transjugular Intrahepatic Portasystemic Shunt 09/2015 - 03/2003
4	Highly Active Antiretroviral Therapy (HAART) 03/2013 - 05/2004
3	Aftercare (After-Treatment) 11/2022 - 03/2018